Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Extensive Stage Small Cell Lung Cancer
NCT05361395Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Aug 2022
- Primary completion
- May 2030
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 15
01
Overview
Phase 1, open-label trial of tarlatamab in small cell lung cancer (SCLC) (9 arms), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicity at 24 months, Treatment-emergent Adverse Events at 24 months and 4 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05361395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361395.